Table I.
Patient baseline demographics
| Baseline demographics | Placebo (n = 20) | rHDL (n = 20) | P value |
|---|---|---|---|
| Age | 72.8 ± 8.31 | 69.0 ± 11.99 | NS |
| Men | 17 (85) | 12 (60) | NS |
| Symptoms | |||
| Amaurosis fugax | 1 (5) | 1 (5) | NS |
| TIA | 10 (50) | 8 (40) | NS |
| Stroke | 9 (45) | 11 (55) | NS |
| Time (days) from index event to CEA | 17.8 ± 8.52 | 17.1 ± 7.10 | NS |
| Risk factors | |||
| Smokinga | 18 (90) | 13 (65) | NS |
| Dyslipidemiab | 19 (95) | 16 (80) | NS |
| Hypertensionc | 20 (100) | 20 (100) | NS |
| Diabetesd | 4 (20) | 3 (15) | NS |
| Previous CVA | 3 (15) | 2 (10) | NS |
| IHDe | 6 (30) | 5 (5) | NS |
| Antiplatelet agent | |||
| Aspirin | 20 (100) | 20 (100) | NS |
| Clopidogrel | 8 (40) | 5 (25) | NS |
| Dipyridamole | 3 (15) | 4 (20) | NS |
| Statins | |||
| Simvastatin 40 mg | 18 (90) | 19 (95) | NS |
| Atorvastatin 20 | 1 (5) | 0 (0) | NS |
| Atorvastatin 40 | 1 (5) | 1 (5) | NS |
Data are expressed as number (percentage) or mean ± SD.
CABG, coronary artery bypass graft; CVA, cardiovascular accident; HMG Co-A, 3-hydroxy-3- methylglutaryl coenzyme A; IHD, ischaemic heart disease; NS, nonsignificant; TIA, transient ischemic attack.
a
Past or present history of smoking.
b
Fasting cholesterol level >5.0 mmol/L and/or use of HMG Co-A reductase inhibitor (statin).
c
Systolic blood pressure >160 mm Hg and/or diastolic blood pressure >90 mm Hg and/or use of antihypertensives.
d
Fasting glucose level >7 mmol/L or insulin and non–insulin-dependent diabetes requiring treatment including diet controlled.
e
Previous history of myocardial infarction/CABG and/or angina requiring treatment.